In the realm of rising stocks, Bright Minds (DRUG) saw a staggering 1445.78% increase. Over the past four days, it rose by 3550.42% consecutively. This surge occurred after Bright Minds Biosciences announced the initiation of its Phase 2 clinical trial to evaluate BMb-101 for drug-resistant epilepsy. The company also ensured financial support extending to 2026, with a webinar scheduled for September 25th.
Energy Vault (NRGV) experienced a 27.72% rise. The company announced its possession of energy storage projects and the commencement of project financing for some of its U.S. endeavors.
Tevogen Bio Holdings (TVGN) climbed by 25.69% and has maintained a four-day consecutive increase, reaching a total rise of 428.35% over this period. Optimism was expressed by Tevogen's CEO, highlighting promising trial data and the potential to integrate T-cell therapies into mainstream treatment.
aTyr Pharma (ATYR) increased by 22.77%, marking an impressive eight-day gain streak of 58.05%. Wells Fargo initiated a recommendation for aTyr Pharma stocks, setting a target price of $17.
Ping An Good Doctor (PGHL) went up by 21.98%, with a three-day rise totaling 31.43%. The company announced a strategic partnership with a major international corporation, which is anticipated to significantly enhance its market competitiveness and profitability. This collaboration is expected to propel Ping An Good Doctor's expansion in global markets and generate new revenue streams.
In contrast, Rani Therapeutics (RANI) fell by 33.33%. The company announced the pricing of a $10 million registered direct offering and the cancellation of some existing warrants.
LexinFintech (LX) saw a 17.93% decrease amid a general decline in Chinese stocks listed in the U.S. after China’s September export figures fell short of expectations.
VNET (VNET) dropped by 16.50% as market concerns arose regarding its recent debt utilization strategy. Investors have begun to question its financial health and future growth potential, possibly impacting its stock price negatively.
ASML (ASML) fell 16.26% following poor performance reports. Its order volume reached only half of market expectations, leading to a downward revision of next year’s sales targets.
CareDx (CDNA) declined by 15.84%. The company projected its third-quarter 2024 operating revenue to be between $82 million and $83 million.